Neuropathology and Molecular Medicine (Friday Plenary Lecture and Saturday Master Class)

Prof Pieter Wesseling, MD, PhD
Amsterdam University Medical Centres/VUmc Amsterdam &
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

 

Pieter Wessling M.D., Ph.D. is a Clinical pathologist/neuropathologist, and full professor in neuro-oncological pathology.

His present affiliations are with the Amsterdam University Medical Centers, Amsterdam (since 2010), and Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (since 2016). He trained in Pathology & Neuropathology (incl. Neurology/Neurosurgery), at the Radboud University Medical Center Nijmegen, Netherland. Fellowship from 1991 – 1992 in Neuropathology/Neuro-oncology Dept. of Pathology, Duke University Medical Center, Durham NC, USA.

Dr Wesseling was Staff member in the Dept. of Pathology, RadboudUMC from 1992 – 2016. In 1997 he wrote a thesis “Angiogenesis in brain tumors; pathobiological and clinical aspects’.

Dr Wesseling has written 275 papers in international, peer-reviewed journals, vast majority of these on neuro-oncological topics; see wesseling-p in PubMed (http://www.ncbi.nlm.nih.gov/pubmed); h-index according to Google Scholar mid-July 2019: 70;

From 1998 to the present he is the Principle investigator of multiple research projects (many of those funded by KWF/Dutch Cancer Society) supervisor/promotor of multiple PhD students/theses.

Since 2000 he is on the Editorial board member of Acta Neuropathologica, Neuro-Oncology, Brain Pathology, Neuropathology & Applied Neurobiology (‘top 5’ neuropathological/neuro-oncological journals); associate editor Neuro-Oncology Practice; frequent ad-hoc reviewer for other international peer-reviewed journals. Co-author on multiple chapters in 4th edition (published in 2007) and revised 4th edition (published in 2016) of WHO Classification of CNS Tumours; invited participant of Consensus and Editorial Meeting for 2016 Classification (Heidelberg, June 2015).

From 2016 to the present: he is an invited member of cIMPACT-NOW (consortium to Inform Molecular and Practical Approaches to
CNS Tumor Taxonomy, i.e. aiming for advancing brain tumor classification) and neuro-oncol. branch ICCR (International Consortium for Cancer Reporting; improving integrated reporting of morphological & molecular findings in CNS tumors).

Furthermore Dr Pieter Wesseling is a member of multiple professional organizations (incl. SNO, AANP, ISN, EURO-CNS, EORTC-BTG), consultant for national and international funding organizations, central reviewing pathologist for several international (EORTC) studies, coordinator EURO-CNS course ‘Tumours of the Central Nervous System and its Coverings’, etc.

Melanocytic and Adnexal Tumour Pathology (Saturday)

Prof Daniela Massi, MD, PhD
Careggi University Hospital, Florence, Italy

Daniela Massi, MD, PhD, is Professor of Pathology at the University of Florence Medical School and Director of the Division of Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.

She trained in Dermatopathology at the Thomas Jefferson University, Philadelphia, and received a post-doctoral research fellowship from the American-Italian Cancer Foundation. She has been Chairman of the Skin Working Group of the European Society of Pathology (ESP) and she is currently Chairman of the EORTC Melanoma Pathology Group and Volume Editor of ‘Pathology & Genetics of Skin Tumours’ of WHO Classification of Tumours series 4th edition.

Her team studies the regulation and function of receptor signaling pathways and the implication of the microenvironment in skin tumor pathology, with particular focus on the identification of prognostic and predictive factors in melanoma. Prof. Massi is Editor-in-Chief of Virchows Archiv since January 2017, having served as Associate Editor for the journal since 2013.

She is the author of over 300 peer-reviewed publications in clinical and translational research in dermatopathology. Professor Massi has presented her work at international and meetings on more than 80 occasions.

Haemopathology (Sunday)

Prof Laurence de Leval, MD, PhD
Lausanne University Hospital, Lausanne, Switzerland

Dr. Laurence de Leval is full Professor of Pathology and Director of the Institute of Pathology at Lausanne University Hospital, Switzerland.  Laurence de Leval graduated M.D. at the University of Liège, Belgium, in 1994, where she trained in pathology and obtained a PhD degree in experimental pathology in 1998.

She completed a 2-year postdoctoral fellowship in hematopathology at the Massachusetts General Hospital, Harvard Medical School, Boston. From 2000 to 2009 she was staff pathologist at the University Hospital, Liège and senior researcher of the Belgian National Fund for Scientific research. She is holding swiss licences for pathology and molecular pathology and her diagnostic activities are mainly in hematopathology and molecular pathology.

Dr. de Leval is an internationally recognized expert in hematopathology. Her research on non-Hodgkin lymphomas was awarded Prize for Clinical Research of the Inbev-Baillet Latour Fund (Belgium) in 2009 and she received the Benjamin Castleman award presented by the United States and Canadian Academy of Pathology in 2008 for her discovery of the follicular helper T-cell (TFH) derivation of angioimmunoblastic T-cell lymphoma. Her current research is focused on exploring the molecular pathogenesis of NK/T-cell malignancies.

Other interests include implementing and optimizing tools for the molecular diagnosis of hematological malignancies and other cancers. Dr. de Leval has authored more than 240 scientific publications and several chapters for reference textbooks in pathology and hematology. She is a member of several national and international scientific societies, member of the pathology working group and co-chair of the T-cell lymphoma working group of the LYSA (the Lymphoma Study Association, France). She was elected member of the International Lymphoma Study Group in 2011, and corresponding member of the Belgian Royal Academy of Medicine.